3.07 (0.99-9.54), p=0.053], even if the difference was only borderline significant because of the reduced sample size.
← all excerpts
Eculizumab in patients with severe coronavirus disease 2019 (COVID-19) requiring continuous positive airway pressure ventilator support: Retrospective cohort study.
2
—
—
The sentences
Between-group differences in ex vivo C5b-9 formation at the same time points and in thrombus deposition at one to four days were highly significant.